A multi-national phase 2 study to assess the efficacy and safety in patients with solid tumor with NTRK fusions
Latest Information Update: 27 Oct 2022
At a glance
- Drugs AUM 601 (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
Most Recent Events
- 20 Oct 2022 According to an AUM Biosciences media release, the company has collaborated with Asymchem to develop and commercially produce AUM 601. The partnership resulted in 10 kg GMP bulk drug substance of AUM 601, which will be used to supply phase 2 trials.
- 21 Apr 2022 New trial record